Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Alamar Biosciences, Inc.NASDAQ: ALMR
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit of $17.72M in Q2 FY2026
Q2 FY2026 gross profit was $17.72M.
Context
- Gross profit amounted to 56.2% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 41.71M USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.71M | — |
Gross Profit vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 gross profit of $41.71M is the 5th highest of the 9 companies compared; the peer median is $50.5M.
- Gross profit amounts to 56.2% of revenue for ALMR, versus a peer median of 48.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $807.58M | +1.5% | +1.3% | 65.8% | |
| LTM Sep 2026 | $444.65M | +0.6% | +3.9% | 71.9% | |
| LTM Sep 2026 | $240.8M | +26.1% | +39.0% | 52.4% | |
| LTM Mar 2026 | $59.34M | +140.9% | +1.1% | 37.1% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $41.71M | — | — | 56.2% |
| LTM Mar 2026 | $41.66M | -37.4% | +4.7% | 48.3% | |
| LTM Mar 2026 | $7.26M | +61.1% | +70.5% | 48.3% | |
| LTM Mar 2026 | $741K | -59.2% | — | 40.0% | |
| LTM Mar 2026 | -$6.32M | +43.5% | — | — | |
| Peer median (excluding ALMR) | $50.5M | +13.8% | +4.3% | 48.3% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.